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ABSTRACT
Introduction Increasingly more pregnant women are 
living with pre- existing multimorbidity (≥two long- term 
physical or mental health conditions). This may adversely 
affect maternal and offspring outcomes. This study aims 
to develop a core outcome set (COS) for maternal and 
offspring outcomes in pregnant women with pre- existing 
multimorbidity. It is intended for use in observational and 
interventional studies in all pregnancy settings.
Methods and analysis We propose a four stage study 
design: (1) systematic literature search, (2) focus groups, 
(3) Delphi surveys and (4) consensus group meeting. The 
study will be conducted from June 2021 to August 2022. 
First, an initial list of outcomes will be identified through 
a systematic literature search of reported outcomes in 
studies of pregnant women with multimorbidity. We will 
search the Cochrane library, Medline, EMBASE and CINAHL. 
This will be supplemented with relevant outcomes from 
published COS for pregnancies and childbirth in general, 
and multimorbidity. Second, focus groups will be conducted 
among (1) women with lived experience of managing pre- 
existing multimorbidity in pregnancy (and/or their partners) 
and (2) their healthcare/social care professionals to identify 
outcomes important to them. Third, these initial lists of 
outcomes will be prioritised through a three- round online 
Delphi survey using predefined score criteria for consensus. 
Participants will be invited to suggest additional outcomes 
that were not included in the initial list. Finally, a consensus 
meeting using the nominal group technique will be held 
to agree on the final COS. The stakeholders will include 
(1) women (and/or their partners) with lived experience of 
managing multimorbidity in pregnancy, (2) healthcare/social 
care professionals involved in their care and (3) researchers 
in this field.
Ethics and dissemination This study has been 
approved by the University of Birmingham’s ethical review 
committee. The final COS will be disseminated through 
peer- reviewed publication and conferences and to all 
stakeholders.
BACKGROUND
Multimorbidity is a state of having two or 
more long- term physical or mental health 
conditions.1 Despite an increase in multi-
morbidity within the general population,2 
there is sparse literature for pregnant women 
with multimorbidity. Studies in the USA 
have reported that between 0.8% and 13.9% 
of hospital births were from women with 
multiple chronic conditions.3 4 Using a list of 
79 chronic conditions, our preliminary study 
found that one in four pregnant women in the 
UK had active multimorbidity at conception.5
Studies have shown that multimorbidity 
is associated with increased risk of adverse 
obstetric outcomes (eg, preterm birth) 
and severe maternal morbidities as a conse-
quence of childbirth (eg, hysterectomy and 
eclampsia).3 4 The 2020 UK national maternal 
mortality review reported that 90% of women 
who died within a year of pregnancy had 
multiple health and social problems.6 The 
Strengths and limitations of this study
 ► Core outcome set (COS) development in accordance 
to the COS standards for development.
 ► Extensive patient, public and stakeholder involve-
ment at each stage.
 ► Pragmatic design to make the COS development 
feasible in the context of multimorbidity.
 ► The applicability of the COS may be limited to high- 
income countries.
 ► Responder bias may influence the types of out-
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leading direct cause of maternal death included throm-
bosis, thromboembolism and maternal suicide; leading 
indirect cause of death included cardiac diseases, epilepsy 
and stroke.6 In addition to acute complications (eg, 
eclampsia) and chronic complications (progression from 
gestational diabetes to type II diabetes) for the mother, 
evidence suggests that pre- existing maternal morbidities 
and medications taken for these morbidities can lead 
to offspring complications such as neurodevelopmental 
disorders and congenital anomalies.4 7–10 Current obser-
vational evidence and interventions focus on single 
morbidities. There is an urgent need for further under-
standing of the consequence of pre- existing maternal 
multimorbidity and development of interventions to 
improve maternity care for these women.11 12
To facilitate future research studies, a core outcome 
set (COS) is required. This will standardise the outcomes 
being reported, allow for evidence synthesis and ensure 
outcomes important to women, their families, carers and 
health and social care professionals are captured.13 The 
importance of COS in women’s health is endorsed by 
the Core Outcomes in Women’s Health initiative.14 The 
Core Outcome Measures in Effectiveness Trial (COMET) 
initiative collates resources for COS development and 
maintains a COS database.15
A recent scoping review identified 26 COSs relevant to 
maternity service users, of which 3 were related to pre- 
existing maternal morbidities in pregnancy (diabetes, 
epilepsy and infertility).16 A search for COS in pregnancy 
on the COMET database further identified two published 
COS (depression and rheumatological conditions) and 
three in progress (cardiac disease, venous thrombo-
embolism and immune thrombocytopenia).15 There is 
currently no COS for multimorbidity in pregnancy. We 
propose a pragmatic study design to develop a COS for 
observational and interventional studies, for pregnant 
women with pre- existing multimorbidity, covering obstet-
rics and maternal and offspring outcomes.
METHODS
This study is designed in accordance with the COS stan-
dards for development Core Outcome Set- STAndardised 
Protocol (COS- STAD) recommendations and the protocol 
follows the COS- STAP statement (online supplemental 
appendix 1); study findings will be reported following 
the COS standards for reporting.17–19 The planned start 
and end dates for the study are June 2021 and August 
2022, respectively. The study is registered on the COMET 
database.20
The study will consist of four stages: (1) systematic liter-
ature search for reported outcomes for mother and child 
in studies of pregnant women with multimorbidity; (2) 
focus groups of women with lived experience of managing 
pre- existing multimorbidity in pregnancy and/or their 
partners, and their healthcare/social care professionals; 
(3) Delphi surveys among stakeholders to prioritise the 
core outcomes and (4) a consensus meeting to agree on 
the final COS (figure 1).
Scope of the COS
The population is pregnant women; the exposure is pre- 
existing multimorbidity, defined as having two or more 
long- term physical or mental health conditions at concep-
tion.1 This does not include pregnancy- related morbidi-
ties (eg, gestational diabetes), which will be considered as 
pregnancy outcomes. The morbidities do not have to be 
independent of each other. For instance, if a morbidity 
is a consequence of another morbidity (eg, diabetic eye 
disease and diabetes), these will be classed as two separate 
morbidities. The COS will be applicable principally to 
observational studies but will also inform interventional 
studies for pregnancy in all settings.
Maternal outcomes will include the antenatal, intra-
partum and postpartum period. Offspring outcomes will 
include the neonatal (first 1 month), infant (first 1 year), 
prepubertal (2–11 years old), pubertal period (12–18 
years old) and adulthood.21 We have included outcomes 
across the lifespan of the offspring to inform observa-
tional studies that take a life- course approach.22 Evidence 
is emerging that pre- existing maternal morbidities can 
impact on offspring long- term health in early adult-
hood.23 Pregnancy outcomes in the rest of this protocol 
will refer to both maternal and offspring outcomes.
Patient and public involvement
This protocol has been shaped by extensive patient and 
public involvement (PPI). PPI for this study will be three- 
tiered: (1) patient representatives in the scientific advi-
sory group (SAG), (2) PPI advisory group and (3) patient 
and public stakeholders as research participants.
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The SAG consists of clinicians (specialists in maternal 
and fetal medicine, obstetrics, perinatal mental health, 
general practice and public health), researchers and 
women representatives collaborating on a larger project 
studying pregnant women with multimorbidity (MuM- 
PreDiCT).24 NM, a women representative from the SAG, 
has advised on the study design, co- authored this protocol 
and created figure 2 that illustrates the PPI in the COS 
development.25
Stage 1: systematic literature search
A pragmatic approach to identifying a list of initial 
outcomes will be adopted given the wide range of poten-
tial multimorbidities. We will first identify outcomes 
from published COS for pregnancy and childbirth and 
published COS for multimorbidity from the COMET 
database.26–29 We will then conduct a systematic literature 
search for reported outcomes in published studies of 
pregnant women with multimorbidity.
Search strategy
The following databases will be searched: Cochrane 
library, Medline, EMBASE and CINAHL. Relevant key 
search terms will include pregnancy (population and 
maternal outcomes), multimorbidity (exposure) and 
offspring (offspring outcomes) derived from previous 
literature.28 30 31
Study selection and data extraction
The inclusion criteria are: systematic reviews, interven-
tional studies, observational studies, qualitative studies 
and patient- reported outcome measures (PROM) studies; 
studies reporting pregnancy, maternal and offspring 
outcomes; and studies of pregnant women with multi-
morbidity. The exclusion criteria are ongoing studies with 
no published outcomes, editorials, commentaries, narra-
tive reviews, case reports, case series, diagnostic accuracy 
studies, laboratory studies and animal studies. No time or 
language limits will be applied. Full text screening will be 
conducted by two independent reviewers.
Two reviewers will extract the following data from 
included studies: author, year of publication, study 
design, PROM domains, types of outcomes, definition of 
and measurement tools for the outcomes. Any discrep-
ancy between the two independent reviewers for study 
selection and data extraction will be resolved with a third 
reviewer.
Stage 2: focus groups
Outcomes identified in the published literature may repre-
sent outcomes considered as important to researchers.13 
Therefore, focus groups will be conducted to ensure the 
capture of outcomes considered as important to women 
with lived experience of managing pre- existing multimor-
bidity in pregnancy and/or their carers/partners (two 
focus groups), and healthcare/social care professionals 
involved in their care (one focus group). The syner-
gistic discussion in focus groups will allow participants 
to consider outcomes which are important to others and 
stimulate in- depth discussions.32
We will aim to include six–eight participants per focus 
group. Sampling will be purposive and guided by the 
sampling matrix to provide a broad representation of 
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stakeholders and characteristics (table 1). Recruitment 
channels are listed in table 2. Involvement of the under-
served population will be guided by our PPI advisory 
group and the MuM- PreDiCT group’s strategy for diverse 
representation.5
Based on the advice of our PPI advisory group, the focus 
groups will be held virtually. Participants will be sent partic-
ipant information sheets in advance of the meeting and 
consent will be taken 24 hours later either in electronic 
form or verbally. The focus group will last for 90 min or 
until no further new ideas are forthcoming. A topic guide 
will be developed based on previous literature, and with 
the guidance of qualitative experts and patient represen-
tatives in the SAG and our PPI advisory group.33 34 The 
focus group will be facilitated by a researcher with quali-
tative methodology training. The focus group discussion 
will be recorded using the virtual meeting platform, the 
recordings will be transcribed and imported to NVivo. 
Data analysis will be inductive, following a structured, 
multistage approach to thematic analysis.35
Initial list of outcomes
The initial list of outcomes generated from stages 1 and 2 
will be reviewed and refined by the SAG and PPI advisory 
group to combine outcomes that are clinically and patho-
physiologically similar to avoid redundancy.13 36 Preg-
nancy outcomes will be categorised by: (1) maternal or 
offspring outcomes and (2) by an established taxonomy 
of outcomes (mortality/survival, physiological/clinical, 
life impact/functioning, resource use and adverse events/
effects).37
Stage 3: Delphi surveys
The Delphi technique collates stakeholder opinions using 
sequential surveys. The response is summarised and fed 
back to stakeholders anonymously in subsequent rounds. 
Stakeholders consider the collective views before re- rating 
the outcomes. This provides a mechanism to reconcile 
different opinions to reach a consensus.13 This study will 
employ a three- round Delphi survey, which is generally 
sufficient to reach consensus (figure 1).38 Participants will 
have the opportunity to suggest additional outcomes that 
were not included in the initial list.
The surveys will be hosted on a secure platform online. 
The three groups of stakeholders that will be invited to 
participate and the recruitment channels are outlined 
in table 2. There is no recommended sample size for 
Delphi surveys; instead of basing the sample size on statis-
tical power, this is often a pragmatic choice.13 Previous 
obstetric COS has achieved sample size of around 
20–40 for patients and 50–100 for healthcare profes-
sionals.36 39–41 To reach the target sample size, snowballing 
recruitment will be encouraged. To check for represen-
tation, the survey will ask for participant characteristics, 
including types of long- term conditions constituting 
multimorbidity, age, ethnicity, education level and socio-
economic status (patient representatives, as outlined in 
table 1), specialty and job roles (healthcare professionals 









(1) Women with lived experience of managing pre- existing multimorbidity (two 
or more long- term conditions) in pregnancy
12–16 50 5
Physical health conditions 6 8–10 1
Mental health conditions 3–6 8–10 1
Ethnic minority 3–6 8–10 2
Socioeconomically disadvantaged/marginalised groups
(eg, homeless, refugee, asylum seeker, drug and alcohol service users, 
disabled people or victims of domestic abuse)6
3–6 8–10 1
(2) Healthcare/social care professionals 6–8 50 5
Obstetric medicine/maternal medicine 1–2 8–10 1
Obstetric 1–2 8–10 1
Midwifery/antenatal practitioner 1–2 8–10 1
Perinatal mental health 1–2 8–10 1
Other: for example, primary care, public health, neonatologist, paediatrician, 
health visitor, commissioner, maternity service provider, social worker, drug and 
alcohol service provider and maternity advocate/educator
2 8–10 1
(3) Researchers
Academics, triallist and journal editors (as future implementers)
– 5–10 2
*NB: Target/minimum numbers are estimates. Due to the overlap of characteristics between participants (eg, physical and mental health 
conditions, healthcare/social care professionals and researchers), we will continuously review the characteristics of participants so that we 
can identify any underrepresented groups and target recruitment efforts in these areas. copyright.
 on D
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and researchers). Participant’s name and email contact 
will be included to avoid duplicate entry, for sending up 
to 2 personalised reminders (1 week apart) and following 
up on incomplete response. This information will be 
kept securely, confidentially and separate from the survey 
responses.
Care will be taken in explaining the concept of COS 
to lay participants, using supporting materials from the 
COMET website.15 The wording of the survey will be 
developed using appropriate language commonly used 
by representatives in the focus groups. The SAG and PPI 
advisory group will also ensure that plain language is used 
to describe the outcomes of interest. Outcomes will be 
presented in alphabetical order to avoid any response 
effects related to the order of survey items.13 42
Each outcome will be rated on a 9- point Likert scale: 
1–3 (not important), 4–6 (important but not critical) and 
7–9 (critically important). An ‘unable to score’ option will 
be provided to allow for participants who may not have 
the expertise to score certain outcomes.13 The 9- point 
Likert scale is commonly used in COS studies and recom-
mended by the Grading of Recommendations Assess-
ment, Development and Evaluation Working Group.13 43
Score criteria for consensus
 ► Consensus in is when ≥70% of all participants rated 
7–9 (critically important) for an outcome.
 ► Consensus out is when≥70% of all participants rated 
1–3 (not important) for an outcome.
 ► No consensus is for any other scores.
Table 2 Stakeholders and recruitment channels
Stakeholder group Potential recruitment channels48 49
(1) Patient representatives
Women with lived experience of managing 
pre- existing multimorbidity (two or more 
long- term physical or mental health 
conditions) in pregnancy and/or their 
partners/carers
 ► Service user associations/groups: for example, Maternity Voice Partnership
 ► Parent support networks: for example, National Childbirth Trust
 ► Community groups: local maternity groups, baby/toddler groups, local authority 
baby class, nursery, health visitor society, faith group and baby groups by 
church
 ► Social media: Facebook, Twitter, Instagram and Linkedin
 ► Parent- oriented social media: home schooling, weaning, budget family menu 
sites, breast feeding, outdoor activities for family, local outdoor groups, 
Mumsnet and Gingerbread (single parents)
 ► Patient support groups/charities for specific conditions: Tommy’s, Epilepsy 
Action, Association of Medical Research UK member charities and National 
Council for Voluntary Organisations
 ► Royal Colleges women’s networks: Royal College of Obstetrics and 
Gynaecology Women’s Voices Involvement Panel, and Royal College of 
Midwifery Maternity Voices Network
 ► Victims of domestic abuse: Refuge, Women’s Aid, WE:ARE (Women’s 
Empowerment and Recovery Educators)
 ► People with disability: Disabled Parents Network, disabled parents Facebook 
groups
 ► Drug and alcohol: Drug and Alcohol Abuse Support for Women
 ► Refugee: Refugee Council, Refugee Survival Trust
 ► LGBT: LGBT Mummies Tribe, Stonewall, Facebook groups for transgender men 
or lesbian women experiencing pregnancy
(2) Healthcare/social care professionals
Any healthcare/social care professionals 
involved in providing multidisciplinary team 
care for pregnant women: for example, 
obstetric physicians, obstetricians, 
physicians, paediatricians, neonatologists, 
psychiatrists, primary care clinicians, 
public health professionals, clinicians of 
established joint antenatal clinics, perinatal 
mental health team, drug and alcohol 
services, social services, midwives, health 
visitors, dieticians, policy- makers and 
commissioners
 ► Personal, professional and clinical network of the researchers
 ► Royal Colleges
 ► Societies (eg, McDonald Obstetric Medicine Society, European Board and 
College of Obstetrics and Gynaecology)
 ► Maternity charities (eg, Ammalife and Elly)
 ► Social media for professional groups (eg, Twitter and Facebook).
(3) Researchers
Academics, triallist and journal editors (as 
future implementers)
The SAG’s personal network, social media (Twitter), the COMET and Core 
Outcomes in Women’s Health (CROWN) network, the Cochrane Pregnancy and 
Childbirth group, and peer- reviewed journals of obstetric medicine and obstetrics
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 ► For further discussion is when: (1) ≥70% of all partic-
ipants rated 4–6 (important but not critical) for an 
outcome, or (2) when ≥70% of patient representatives 
have rated 7–9 for an outcome but consensus in is not 
reached.44
Pilot study
The survey will be piloted before the Delphi rounds to 
check face validity. It will also inform the time frame 
required for completion of each Delphi round.
First Delphi
Participants will be sent a participant information sheet 
explaining the objectives of the COS study. Completion of 
the online survey assumes implied consent. Participants 
will be informed that they can withdraw their response 
from the study within 1 week of submitting the survey. 
Once the name and contact details are separated from 
the survey response, it will not be possible to withdraw 
their survey response.
At the end of the survey, an open question will invite 
participants to suggest a maximum of two additional 
outcomes. If a new outcome is suggested by two or more 
participants, it will then be added to the second Delphi 
round. Depending on how many new outcomes that will 
be presented, this criterion may be modified on a prag-
matic basis.
Secound Delphi
Participants who responded to the first Delphi round will 
be invited to participate in the second Delphi. A summary 
response from the first Delphi stratified by stakeholder 
groups will be presented for all outcomes.
Third Delphi
Participants who responded to the second Delphi 
round will be invited to participate in the third Delphi. 
Outcomes that reached no consensus will be included as 
options in the third Delphi survey. A summary response 
from the second Delphi round stratified by stakeholder 
groups will also be presented. Attrition rate will be calcu-
lated for each subsequent rounds.
Stage 4: consensus meeting
At the time of writing, the UK is undergoing social 
distancing due to the COVID- 19 pandemic. In addition, 
our SAG patient representative has advised that travel-
ling to meetings may not be convenient for mothers with 
childcare needs. Therefore, the consensus meeting will 
be conducted through a virtual platform online.
The consensus meeting panel will be purposefully 
selected from the SAG, PPI advisory group and Delphi 
survey respondents to ensure representation of a range of 
backgrounds. In the third Delphi survey, participants will 
be asked about their willingness to attend the consensus 
meeting. For meaningful engagement in the consensus 
meeting, we will aim for 10–15 participants.13 25 42
An experienced facilitator will be the non- voting chair. 
Summary scores stratified by stakeholder groups will be 
presented for outcomes that met the ‘for further discus-
sion’ criteria. Nominal group technique will be used to 
discuss these outcomes.44 45 Participants will be asked 
to contemplate independently whether these outcomes 
should be included. Each participant will be invited to 
voice their reasoning in turn using a round- robin format 
to avoid domination of the discussion by selected few. This 
will be followed by an open discussion, after which a final 
anonymous binary vote of yes/no will be conducted for 
each of these outcomes. Outcomes that received ≥70% 
yes votes will be included in the final COS.
DISCUSSION
The proposed COS will be applicable for observational 
and interventional studies for pregnant women with pre- 
existing multimorbidity. Further interventional studies 
are urgently needed to tackle multimorbidity in preg-
nancy and reduce the associated adverse outcomes. It is, 
therefore, important to have a predefined COS to inform 
future research studies to enable valid comparisons 
between study findings.
Strength
There is currently no COS for studies of pregnant women 
with multimorbidity. As multimorbidity covers a wide 
range of diseases, this presents a unique methodological 
challenge to the COS development. This study aims to 
adopt a pragmatic approach to make the task manageable 
while still following the COS- STAD minimum standards. 
Inclusion of observational studies in generating the initial 
list of outcomes may detect rare but important clinical 
outcomes especially for offspring.46
The Delphi surveys, nominal group technique and anon-
ymous final vote in the consensus meeting will encourage 
participation of all stakeholders and avoid dominance of 
selected figures. As outlined in figure 2, PPI will have a 
meaningful role throughout the COS development to 
ensure accessibility and relevance to patient stakeholder 
groups and that patient perspectives are represented in 
the governance of the COS development.25
To widen its applicability, the proposed COS will include 
both maternal and offspring outcomes and will include 
outcomes that are common to all pregnant women with 
multimorbidity. Finally, by creating this COS, we hope to 
encourage and facilitate urgently needed research for 
pregnant women with multimorbidity.
Limitation
The focus groups, Delphi survey and consensus meeting 
will be conducted in English. Although efforts will be 
made to encourage international participation, this may 
limit the generalisability of the findings to high- income 
countries. The use of online platforms may lead to under-
representation of the digitally disadvantaged groups. 
Similarly, responder bias may influence the types of 
outcomes included in the final COS. To ensure repre-
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group and healthcare/social care professionals with busy 
work schedules, our approach will be flexible and where 
necessary/preferred by the participants, we will offer the 
option of one- to- one interviews instead of focus groups.
As further epidemiological knowledge is gained in 
identifying common morbidity clusters in pregnant 
women, the COS may need to be updated to incorporate 
outcomes specific to these clusters.
DISSEMINATION
The final COS will be fed back to all stakeholders. Patient 
and public representatives will be encouraged and 
supported to share the difference they have made. With 
the guidance of the SAG and the PPI advisory group, a 
collaborative dissemination plan will be formulated. This 
will include submitting the findings for publication in a 
peer- reviewed journal, dissemination at conferences and 
registering the study on the COMET database.
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